Author:
Mezochow Alyssa K.,He Kevin D.,Whitaker Kathryn,Blumberg Emily,Crespo Maria M.,Courtwright Andrew
Funder
National Institute of Allergy and Infectious Diseases
Reference15 articles.
1. Letermovir for the prevention of cytomegalovirus infection and disease in transplant recipients: an evidence-based review;El Helou;Infect Drug Resist,2019
2. What’s new: updates on cytomegalovirus in solid organ transplantation;Stewart;Transplantation,2024
3. Cytomegalovirus high-risk kidney transplant recipients show no difference in long-term outcomes following preemptive versus prophylactic management;Blom;Transplantation,2023
4. FDA medical review. Approval package for PREVYMIS; 2018. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209939Orig1s000,209940Orig1s000Approv.pdf, accessed March 5, 2024.
5. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation;Marty;N Engl J Med,2017